Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Bicara Therapeutics to post earnings of ($0.31) per share for the quarter.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $13.82 on Friday. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09. The stock has a fifty day moving average of $14.49.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Rodman & Renshaw assumed coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price target on the stock. HC Wainwright lifted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Finally, RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Bicara Therapeutics presently has an average rating of “Buy” and an average target price of $41.20.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.